ContraVir Pharma

CTRV NASDAQ
3.560
-0.060
-1.66%
After Hours: 3.580 +0.02 +0.56% 16:38 07/19 EDT
Open
3.590
Prev Close
3.620
High
3.670
Low
3.560
Volume
109.63K
Avg Vol (3M)
814.70K
52 Week High
91.00
52 Week Low
3.520
% Turnover
13.66%
Market Cap
2.86M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ContraVir Pharma CTRV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver high intrahepatic concentrations of TFV while minimizing off target effects caused by high levels of circulating TFV, and has completed a Phase IIa trial. CRV431, the other anti-HBV compound, is a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg).
MORE >

Recently

Name
Price
%Change